BL-M09D1

Phase 2Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

BL-M09D1 is one of 69 small molecule programs targeting Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalignanciesNot yet recruiting

Gastrointestinal TumorsRecruiting

Non-Small Cell Lung CancerRecruiting

MalignanciesPhase 2

Not yet recruiting

Gastrointestinal TumorsPhase 1

Recruiting

Non-Small Cell Lung CancerPhase 1

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 2

Anktiva

SSWOG Cancer Research Network

Phase 3

1 3

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 4

BL-M09D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Non-Small Cell Lung Cancer

NCT07056556

Phase 1Recruiting

Gastrointestinal Tumors

NCT06954077

Q4 2028

Phase 2Not yet recruiting

Malignancies

NCT07769229

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT07056556·31 enrolled

Gastrointestinal Tumors1 trial

A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06954077·45 enrolled

Malignancies1 trial

A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M09D1 for Injection in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid Tumors

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT07769229·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BL-M09D1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BL-M09D1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BL-M09D1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

BL-M09D1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Gastrointestinal Tumors1 trial

Malignancies1 trial

References

Drug Info

Quick Facts

Related News